Compounding Pharmacies in European Union: Market Size, Businesses & Forecast 2026

The compounding pharmacies industry in the European Union focuses on the preparation of customized medications, historically known as magistral and officinal formulae, to address specific patient needs that commercial drugs cannot meet. The industry is steering toward stricter quality standardization under individual Member State authorities while navigating the exclusion of pharmacy-prepared products from the broader EU Community code on medicinal products. Growth is qualitatively driven by the expansion of personalized medicine, customized hormone replacement therapies, and localized shortages of industrially manufactured pharmaceuticals. As an industry primarily integrated into local heal

Industry snapshot

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Compounding Pharmacies in European Union industry cover?

The compounding pharmacy sector in the European Union encompasses the non-industrial preparation of medicinal products customized for individual patients or specific pharmacy clienteles. Under EU pharmaceutical law, these activities are categorized into two primary types that fall outside the main scope of commercial marketing authorizations. The first is the magistral formula, which is prepared in a pharmacy according to a specific medical prescription for an individual patient. The second is the officinal formula, which is prepared inside a pharmacy following the guidelines of an official pharmacopoeia and intended for direct supply to that pharmacy's own patients.

• •Governed fundamentally by Article 3 of Directive 2001/83/EC, which explicitly excludes magistral and officinal formulations from the standard EU Community code for medicinal products for human use.
• •Preparation environments range from traditional community retail pharmacies to highly specialized, sterile hospital pharmacy compounding units.
• •Scope includes altering dosages, removing allergenic excipients, and preparing custom topical or injectable medications that lack an industrial equivalent.

Who operates in the industry and how is it structured?

The sector's structure within the EU is highly decentralized and fragmented, primarily because the regulatory authority over non-industrial compounding remains with individual Member States. Operators include community retail pharmacies, hospital pharmacies, and specialized compounding compounding facilities that distribute raw active pharmaceutical ingredients (APIs). Because compounding is tied to localized pharmacy licenses rather than separate industrial manufacturing permits, market density corresponds heavily with national healthcare infrastructures.

• •Dominated by a vast network of independent community pharmacies alongside specialized hospital procurement departments.
• •European B2B suppliers provide standardized raw chemicals, specialized compounding equipment, and software to local pharmacies to ensure uniform compounding quality.
• •Operators face varying limits across borders, such as the Netherlands' localized restriction limiting specific officinal formula distributions to a 'small scale' threshold.

What drives demand in the industry?

Demand for compounding services across the European Union is driven by structural shifts toward customized patient care and ongoing disruptions in the traditional pharmaceutical supply chain. The growing geriatric demographic requires tailored dosage forms, such as liquid alternatives for patients suffering from dysphagia. Additionally, frequent shortages of commercially manufactured medicines prompt clinicians to rely on magistral formulations to maintain continuity of care.

• •Increasing clinical requirements for allergen-free formulations, such as medications prepared without specific dyes, gluten, or preservatives.
• •High demand for customized hormone replacement therapy (HRT) and specialized dermatological compounds tailored to individual skin tolerances.
• •Mitigation of European medicine shortages, allowing hospital pharmacies to compound critical treatments using bulk active ingredients when commercial packs are unavailable.

Who are the notable companies in the industry?

The commercial landscape supporting EU compounding is led by multinational entities that supply raw active ingredients, vehicle bases, and formulation technology to individual compounding pharmacies, alongside major European healthcare providers that run localized compounding operations. Due to the decentralized nature of direct-to-patient compounding, major players focused heavily on consolidating the business-to-business supply chain. These entities operate across multiple EU borders to standardize compounding methodologies.

• •Fagron N.V., a major publicly traded European company, specializes extensively in providing compounding essentials, raw materials, and customized formulations to pharmacies globally.
• •Fresenius Kabi AG operates widespread compounding services across Europe, focusing primarily on sterile compounding, clinical nutrition, and oncology admixtures for hospital networks.
• •B. Braun Melsungen AG engages in specialized healthcare solutions, providing precise compounding systems and sterile automated mixing technologies used throughout European clinical facilities.
• •Euroapi S.A., a major European active pharmaceutical ingredient (API) manufacturer, supports the industry by producing and distributing high-quality chemical inputs required for pharmacy formulations.

What are the recent trends and outlook?

The European compounding landscape is experiencing heightened scrutiny regarding the scale of production and the boundaries between compounding and industrial manufacturing. A landmark legal precedent from the Court of Justice of the European Union (CJEU) affirmed that Member States hold full regulatory discretion to cap the quantities of pharmacy-prepared medications. Looking forward, the sector is anticipating further alignment as the broader EU Pharmaceutical Package undergoes revision, balancing patient access to customized medication with strict safety guardrails.

• •The CJEU Case C-589/24 ruling validated that national authorities can legally restrict the supply of officinal formulas using specific quantitative limits per month.
• •Increased adoption of advanced pharmacy automation systems to mitigate human error in sterile and non-sterile compounding workflows.
• •Growing friction between multinational marketing authorization holders and independent compounding pharmacies over the preparation of products containing identical active ingredients to commercial drugs.

How is the industry regulated?

Compounding pharmacies in the EU must adhere to a complex legal framework divided between EU-wide exemptions and stringent national oversight. Because compounding is excluded from centralized European Medicines Agency (EMA) marketing authorization paths, national competent authorities dictate specific compliance practices. These laws dictate strict adherence to national or European pharmacopoeias and Good Preparation Practices to guarantee product sterility and patient safety.

• •Compliance is anchored to national legislation that implements the exclusions detailed in EU Directive 2001/83/EC.
• •Formulations must be prepared in strict accordance with recognized official standards, such as the European Pharmacopoeia or individual national equivalents.
• •Member States enforce localized Good Manufacturing Practices (GMP) or specific Good Preparation Practices for pharmacies handling hazardous or sterile compounds.

Government, statistical and trade sources used for this Claight analysis.

• European Medicines Agency (EMA) Industrial and Regulatory Guidelines 2025/2026 ·
• Court of Justice of the European Union (CJEU) Judgment Case C-589/24 ·
• European Parliament and Council Directive 2001/83/EC ·
• Eurostat NACE Rev. 2 Statistical Classification Manual